Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study.
Carrie L KitkoMukta AroraZachariah DeFilippMohammad Abu ZaidAntonio Di StasiVedran RadojcicCourtney B BettsLisa M CoussensMichael L MeyersHope QamoosPeter OrdentlichVinit KumarChristine QuarantoAaron SchmittYu GuBruce R BlazarTrent P WangAmandeep SalhotraIskra PusicMadan JagasiaStephanie J LeePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Targeting profibrotic macrophages with axatilimab is a therapeutically promising novel strategy with a favorable safety profile for refractory cGVHD.
Keyphrases